How much revenue did Laboratorios Farmaceuticos ROVI generate this year?
Laboratorios Farmaceuticos ROVI has achieved a revenue of 816.82 M EUR this year.
In 2024, Laboratorios Farmaceuticos ROVI's sales reached 816.82 M EUR, a -1.53% difference from the 829.51 M EUR sales recorded in the previous year.
YEAR | REVENUE (undefined EUR) | GROSS MARGIN (%) |
---|---|---|
2028e | 1.3 | 37,93 |
2027e | 1.25 | 39,26 |
2026e | 1.08 | 45,50 |
2025e | 0.9 | 54,90 |
2024e | 0.82 | 60,27 |
2023 | 0.83 | 59,35 |
2022 | 0.82 | 63,55 |
2021 | 0.65 | 59,32 |
2020 | 0.42 | 57,46 |
2019 | 0.38 | 56,31 |
2018 | 0.3 | 57,58 |
2017 | 0.28 | 60,77 |
2016 | 0.27 | 57,75 |
2015 | 0.25 | 60,54 |
2014 | 0.24 | 60,27 |
2013 | 0.22 | 60,98 |
2012 | 0.2 | 62,61 |
2011 | 0.18 | 62,43 |
2010 | 0.16 | 60,40 |
2009 | 0.14 | 67,28 |
2008 | 0.13 | 72,31 |
2007 | 0.1 | 68,22 |
2006 | 0.11 | 71,81 |
2005 | 0.08 | 71,91 |
2004 | 0.06 | 68,60 |
3 years
5 years
10 years
25 Years
Max
Gain insights into Laboratorios Farmaceuticos ROVI, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Laboratorios Farmaceuticos ROVI from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Laboratorios Farmaceuticos ROVI’s net earnings, an ultimate measure of its financial health and profitability.
Observe the yearly bars to understand the annual performance and growth of Laboratorios Farmaceuticos ROVI. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
The expected values for the forthcoming years offer investors a glimpse into Laboratorios Farmaceuticos ROVI’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Leveraging the comparison between Revenue and EBIT helps in assessing Laboratorios Farmaceuticos ROVI’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Laboratorios Farmaceuticos ROVI’s growth potential.
Date | Laboratorios Farmaceuticos ROVI Revenue | Laboratorios Farmaceuticos ROVI EBIT | Laboratorios Farmaceuticos ROVI Net Income |
---|---|---|---|
2028e | 1.3 B undefined | 463.34 M undefined | 388.24 M undefined |
2027e | 1.25 B undefined | 458.67 M undefined | 333.96 M undefined |
2026e | 1.08 B undefined | 353.56 M undefined | 262.04 M undefined |
2025e | 896.72 M undefined | 259.92 M undefined | 194.58 M undefined |
2024e | 816.82 M undefined | 215.51 M undefined | 160.07 M undefined |
2023 | 829.51 M undefined | 220.25 M undefined | 170.34 M undefined |
2022 | 817.7 M undefined | 255.85 M undefined | 199.67 M undefined |
2021 | 648.68 M undefined | 183.07 M undefined | 153.08 M undefined |
2020 | 419.96 M undefined | 78.77 M undefined | 61.06 M undefined |
2019 | 381.31 M undefined | 43.18 M undefined | 39.27 M undefined |
2018 | 303.2 M undefined | 17.46 M undefined | 17.9 M undefined |
2017 | 275.65 M undefined | 19.01 M undefined | 17.24 M undefined |
2016 | 265.17 M undefined | 28.3 M undefined | 26.09 M undefined |
2015 | 246.01 M undefined | 21.84 M undefined | 19.81 M undefined |
2014 | 238.05 M undefined | 27.43 M undefined | 24.12 M undefined |
2013 | 217.6 M undefined | 25.4 M undefined | 23 M undefined |
2012 | 201.9 M undefined | 21.7 M undefined | 19.5 M undefined |
2011 | 184.7 M undefined | 19 M undefined | 18.1 M undefined |
2010 | 158.6 M undefined | 26 M undefined | 24.6 M undefined |
2009 | 141.8 M undefined | 25.5 M undefined | 20.1 M undefined |
2008 | 127.5 M undefined | 28.3 M undefined | 23.5 M undefined |
2007 | 100.7 M undefined | 18.4 M undefined | 15 M undefined |
2006 | 105 M undefined | 13.4 M undefined | 10.9 M undefined |
2005 | 82.6 M undefined | 3.3 M undefined | 4.1 M undefined |
2004 | 63.7 M undefined | 3.5 M undefined | 14.5 M undefined |
Revenue | EBIT | Net Income | |
---|---|---|---|
2004 | 63.7 M EUR | 3.5 M EUR | 14.5 M EUR |
2005 | 82.6 M EUR | 3.3 M EUR | 4.1 M EUR |
2006 | 105 M EUR | 13.4 M EUR | 10.9 M EUR |
2007 | 100.7 M EUR | 18.4 M EUR | 15 M EUR |
2008 | 127.5 M EUR | 28.3 M EUR | 23.5 M EUR |
2009 | 141.8 M EUR | 25.5 M EUR | 20.1 M EUR |
2010 | 158.6 M EUR | 26 M EUR | 24.6 M EUR |
2011 | 184.7 M EUR | 19 M EUR | 18.1 M EUR |
2012 | 201.9 M EUR | 21.7 M EUR | 19.5 M EUR |
2013 | 217.6 M EUR | 25.4 M EUR | 23 M EUR |
2014 | 238.05 M EUR | 27.43 M EUR | 24.12 M EUR |
2015 | 246.01 M EUR | 21.84 M EUR | 19.81 M EUR |
2016 | 265.17 M EUR | 28.3 M EUR | 26.09 M EUR |
2017 | 275.65 M EUR | 19.01 M EUR | 17.24 M EUR |
2018 | 303.2 M EUR | 17.46 M EUR | 17.9 M EUR |
2019 | 381.31 M EUR | 43.18 M EUR | 39.27 M EUR |
2020 | 419.96 M EUR | 78.77 M EUR | 61.06 M EUR |
2021 | 648.68 M EUR | 183.07 M EUR | 153.08 M EUR |
2022 | 817.7 M EUR | 255.85 M EUR | 199.67 M EUR |
2023 | 829.51 M EUR | 220.25 M EUR | 170.34 M EUR |
2024e | 816.82 M EUR | 215.51 M EUR | 160.07 M EUR |
2025e | 896.72 M EUR | 259.92 M EUR | 194.58 M EUR |
2026e | 1.08 B EUR | 353.56 M EUR | 262.04 M EUR |
2027e | 1.25 B EUR | 458.67 M EUR | 333.96 M EUR |
2028e | 1.3 B EUR | 463.34 M EUR | 388.24 M EUR |
3 years
5 years
10 years
25 Years
Max
The gross margin, expressed as a percentage, delineates the gross profit made from the Laboratorios Farmaceuticos ROVI's sales revenue. A higher gross margin percentage indicates that the Laboratorios Farmaceuticos ROVI retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT margin represents the Laboratorios Farmaceuticos ROVI's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
The revenue margin demonstrates the Laboratorios Farmaceuticos ROVI's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Laboratorios Farmaceuticos ROVI's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Laboratorios Farmaceuticos ROVI. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Laboratorios Farmaceuticos ROVI's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Laboratorios Farmaceuticos ROVI Gross margin | Laboratorios Farmaceuticos ROVI Profit margin | Laboratorios Farmaceuticos ROVI EBIT margin | Laboratorios Farmaceuticos ROVI Profit margin |
---|---|---|---|
2028e | 59.35 % | 35.7 % | 29.91 % |
2027e | 59.35 % | 36.58 % | 26.63 % |
2026e | 59.35 % | 32.68 % | 24.22 % |
2025e | 59.35 % | 28.99 % | 21.7 % |
2024e | 59.35 % | 26.38 % | 19.6 % |
2023 | 59.35 % | 26.55 % | 20.53 % |
2022 | 63.55 % | 31.29 % | 24.42 % |
2021 | 59.32 % | 28.22 % | 23.6 % |
2020 | 57.46 % | 18.76 % | 14.54 % |
2019 | 56.31 % | 11.33 % | 10.3 % |
2018 | 57.58 % | 5.76 % | 5.9 % |
2017 | 60.77 % | 6.9 % | 6.25 % |
2016 | 57.75 % | 10.67 % | 9.84 % |
2015 | 60.54 % | 8.88 % | 8.05 % |
2014 | 60.27 % | 11.52 % | 10.13 % |
2013 | 60.98 % | 11.67 % | 10.57 % |
2012 | 62.61 % | 10.75 % | 9.66 % |
2011 | 62.43 % | 10.29 % | 9.8 % |
2010 | 60.4 % | 16.39 % | 15.51 % |
2009 | 67.28 % | 17.98 % | 14.17 % |
2008 | 72.31 % | 22.2 % | 18.43 % |
2007 | 68.22 % | 18.27 % | 14.9 % |
2006 | 71.81 % | 12.76 % | 10.38 % |
2005 | 71.91 % | 4 % | 4.96 % |
2004 | 68.6 % | 5.49 % | 22.76 % |
Gross margin | EBIT margin | Profit margin | |
---|---|---|---|
2004 | 68.6 % | 5.49 % | 22.76 % |
2005 | 71.91 % | 4 % | 4.96 % |
2006 | 71.81 % | 12.76 % | 10.38 % |
2007 | 68.22 % | 18.27 % | 14.9 % |
2008 | 72.31 % | 22.2 % | 18.43 % |
2009 | 67.28 % | 17.98 % | 14.17 % |
2010 | 60.4 % | 16.39 % | 15.51 % |
2011 | 62.43 % | 10.29 % | 9.8 % |
2012 | 62.61 % | 10.75 % | 9.66 % |
2013 | 60.98 % | 11.67 % | 10.57 % |
2014 | 60.27 % | 11.52 % | 10.13 % |
2015 | 60.54 % | 8.88 % | 8.05 % |
2016 | 57.75 % | 10.67 % | 9.84 % |
2017 | 60.77 % | 6.9 % | 6.25 % |
2018 | 57.58 % | 5.76 % | 5.9 % |
2019 | 56.31 % | 11.33 % | 10.3 % |
2020 | 57.46 % | 18.76 % | 14.54 % |
2021 | 59.32 % | 28.22 % | 23.6 % |
2022 | 63.55 % | 31.29 % | 24.42 % |
2023 | 59.35 % | 26.55 % | 20.53 % |
2024e | 59.35 % | 26.38 % | 19.6 % |
2025e | 59.35 % | 28.99 % | 21.7 % |
2026e | 59.35 % | 32.68 % | 24.22 % |
2027e | 59.35 % | 36.58 % | 26.63 % |
2028e | 59.35 % | 35.7 % | 29.91 % |
The sales figures of Laboratorios Farmaceuticos ROVI originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Analyzing Laboratorios Farmaceuticos ROVI’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Investors often scrutinize Laboratorios Farmaceuticos ROVI's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Increases in Laboratorios Farmaceuticos ROVI’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Laboratorios Farmaceuticos ROVI has achieved a revenue of 816.82 M EUR this year.
The revenue of Laboratorios Farmaceuticos ROVI has increased by -1.53% decreased compared to the previous year.
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
The revenue of Laboratorios Farmaceuticos ROVI is influenced by various factors, including the demand for its products and services, market conditions, and prices.
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
The revenue of Laboratorios Farmaceuticos ROVI is an important indicator of financial performance and attractiveness for investors.
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
Over the past 12 months, Laboratorios Farmaceuticos ROVI paid a dividend of 1.29 EUR . This corresponds to a dividend yield of about 1.74 %. For the coming 12 months, Laboratorios Farmaceuticos ROVI is expected to pay a dividend of 1.69 EUR.
The current dividend yield of Laboratorios Farmaceuticos ROVI is 1.74 %.
Laboratorios Farmaceuticos ROVI pays a quarterly dividend. This is distributed in the months of August, August, August, August.
Laboratorios Farmaceuticos ROVI paid dividends every year for the past 21 years.
For the upcoming 12 months, dividends amounting to 1.69 EUR are expected. This corresponds to a dividend yield of 2.27 %.
Laboratorios Farmaceuticos ROVI is assigned to the 'Health' sector.
To receive the latest dividend of Laboratorios Farmaceuticos ROVI from 7/10/2024 amounting to 1.104 EUR, you needed to have the stock in your portfolio before the ex-date on 7/8/2024.
The last dividend was paid out on 7/10/2024.
In the year 2023, Laboratorios Farmaceuticos ROVI distributed 0.956 EUR as dividends.
The dividends of Laboratorios Farmaceuticos ROVI are distributed in EUR.
Our stock analysis for Laboratorios Farmaceuticos ROVI Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Laboratorios Farmaceuticos ROVI Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.